Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares rose 5.7% during mid-day trading on Wednesday . The stock traded as high as $0.60 and last traded at $0.54, approximately 188,816 shares traded hands during mid-day trading. A decline of 53% from the average daily volume of 401,295 shares. The stock had previously closed at $0.51.
CYCC has been the topic of several recent research reports. ValuEngine raised Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research upgraded Cyclacel Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $0.50 price objective for the company in a report on Monday, November 18th.
The company has a market cap of $9.46 million, a P/E ratio of -0.87 and a beta of 3.19. The company has a fifty day moving average price of $0.42 and a two-hundred day moving average price of $0.49. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.65 and a current ratio of 7.65.
Cyclacel Pharmaceuticals Company Profile (NASDAQ:CYCC)
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Featured Story: Why is cost of goods sold important?
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.